Chugai wins licence dispute concerning US patent in UK High Court
The English High Court has ruled that Chugai no longer needs to pay royalties for its antibody product because it does not fall within the claims of UCB’s US patent
In a decision that nicely summarises US law and provides lessons on licence and patent drafting, the UK High Court has ruled that Chugai does not need to pay royalties to UCB for its tocilizumab products.
Mr Justice Birss decided...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.